David Mallery, JD, MBA

Co-founder and President for Paradigm
International Genomics Consortium

David Mallery, J.D., MBA is a co-founder and the President of Viomics, Inc., the International Genomics Consortium (IGC) and Paradigm Diagnostics, and was formerly the founder of the Molecular Profiling Institute (MPI) and was the President of Caris MPI following the successful acquisition. Viomics has discovered and is finalizing exceptionally accurate blood RNA markers for a variety of cancers.  IGC is instrumental for the biospecimen accrual, amplification, and processing aspects of The Cancer Genome Atlas project for the National Cancer Institute. David launched and helped commercialize many of the top diagnostics in oncology today including Target Now (renamed MI Profile offered through Caris), the Progensa PCA3 prostate screen from Gen-Probe which recently received FDA registration, and Agendia’s MammaPrint. Through Paradigm, a joint-venture with the University of Michigan, Mr. Mallery is also helping launch an evidence driven sequencing based multiplex diagnostic for late stage and difficult to treat solid tumors.

David has a BA in Human Biology and Art from Stanford and a JD/MBA from the University of Colorado, is a life member of the Council on Foreign Relations, and is a member of the Colorado and D.C. Bar Associations.